This is an exploratory clinical study of Human Anti-PD-L1 Monoclonal Antibody Injection (LDP)
combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)
in patients with advanced malignant tumor.
This is an open, dose-escalation and dose-extension exploratory clinical study for patients
with advanced malignancy who have failed standard therapy. In the dose-escalation phase, a
fixed dose of CDP1 will be given once a week, while LDP will be given every two weeks with
dose climbing. Then, cohort studies (cohorts 1 to 5) will be conducted during the
dose-expansion phase. The purpose is to preliminarily evaluate the safety and efficacy of LDP
combined with CDP1 in the treatment of patients with advanced malignant tumor, and to
determine the recommended dose for clinical trial.
Advanced Malignant Tumor
Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.